Izotropic(OTC) IZOZF

Market Cap$8.92M

Since IPO (2019)-53%

5 Year-85%

1 Year-50%

1 Month-16%

$0.11

-10.31%

-0.01Today

Izotropic last closing stock price
Metric	Price	Date
Last close	USD 0.13	2026-10-13

Izotropic stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9.65%	USD 0.12	2026-10-06
1 month	-15.84%	USD 0.15	2026-09-10
3 month	-28.89%	USD 0.18	2026-07-15
Year to date	-36.95%	USD 0.20	2025-12-31
1 year	-50.29%	USD 0.26	2025-10-13
3 year	-21.59%	USD 0.16	2023-10-12
5 year	-85.45%	USD 0.88	2021-10-14
Since inception	-53.45%	USD 0.28	2019-03-12

Izotropic Financials at a Glance

Market Cap

$8.92M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$2.29M

EPS (TTM)

-$0.02

P/E Ratio

-5.22

Dividend

$0.00

Beta (Volatility)

0.20 (Low)

Dividend

$0.00

Beta (Volatility)

0.20 (Low)

Price

$0.11

Volume

37,762

Open

$0.15

Price

$0.11

Volume

37,762

Open

$0.15

Previous Close

$0.13

Daily Range

$0.10 - $0.15

52-Week Range

$0.10 - $0.37

Estimated Earnings Date

Mar 30, 2026

Dividend

$0.00

Beta (Volatility)

0.20 (Low)

Price

$0.11

Volume

37,762

Open

$0.15

Previous Close

$0.13

Daily Range

$0.10 - $0.15

52-Week Range

$0.10 - $0.37

Estimated Earnings Date

Mar 30, 2026

IZOZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Izotropic

Izotropic Corporation is a medical technology company dedicated to advancing diagnostic solutions for breast cancer. The firm specializes in developing and selling a specialized breast CT imaging system and a 3D CT breast imaging platform, aimed at enhancing early detection and accurate diagnosis of breast cancer.

Products and Services

Specialized breast CT imaging system for enhanced diagnostics
3D CT breast imaging platform for improved detection
Research and development focused on innovative medical technologies

Growth Outlook

Significant market potential in breast cancer diagnostics
Continued investment in research and development initiatives
Strategic partnerships to enhance product offerings and market reach

Financial Highlights

Recent quarterly net income of -$533,728, reflecting ongoing investment in R&D
Trailing twelve months (TTM) revenue of $0, indicating a focus on product development
Cash and cash equivalents of $57,810 as of July 31, 2026

Izotropic Corporation operates in the medical diagnostics and research industry, with a focus on breast cancer detection technologies. The company has positioned itself to address a critical need in healthcare, as early detection significantly improves treatment outcomes. Despite recent financial challenges, including a net income loss, the commitment to research and development remains strong, indicating a long-term vision for growth and innovation. The current cash position allows for continued operational activities while pursuing strategic partnerships to expand market presence. Investors may find the company's focus on advanced diagnostic solutions appealing, given the increasing demand for effective breast cancer screening technologies.

AI Generated • Oct 7, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Robert Louis Thast

Website

www.izocorp.com

Headquarters

Surrey, BC V4A 2H9, CA

IZOZF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

40.45%

Return on Capital

N/A

Return on Assets

-848.96%

Earnings Yield

-19.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.92M

Shares Outstanding

69.72M

Volume

37.76K

Avg. Volume

18.20K

Financials (TTM)

Gross Profit

-CA$33.89K

Operating Income

-CA$1.49M

EBITDA

-CA$1.46M

Operating Cash Flow

-CA$733.69K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$733.69K

Cash & ST Invst.

CA$57.81K

Total Debt

CA$3.21M

Izotropic Performance Analysis

Izotropic annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-04-30	CAD 0	N/A
2024	2024-04-30	CAD 0	N/A
2025	2025-04-30	CAD 0	N/A
2026	2026-04-30	CAD 0	N/A

Izotropic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-10-31	N/A
Q3	2026-01-31	N/A
Q4	2026-04-30	N/A
Q1	2026-07-31	N/A

Izotropic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-04-30	CAD -0.09	-31.0%
2024	2024-04-30	CAD -0.02	-74.7%
2025	2025-04-30	CAD -0.04	78.6%
2026	2026-04-30	CAD -0.02	-38.3%

Izotropic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-10-31	-152.1%
Q3	2026-01-31	66.9%
Q4	2026-04-30	-155.0%
Q1	2026-07-31	24.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2027YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$11.18K

-45.4%

Gross Margin

0.00%

N/A

Market Cap

$8.92M

N/A

Market Cap/Employee

$1.78M

N/A

Employees

N/A

Net Income

-CA$533.73K

-25.6%

EBITDA

-CA$343.84K

-16.4%

Quarterly Fundamentals

Name

Q1 2027YOY CHG

Total Cash

CA$57.81K

+18.9%

Total Debt

CA$3.21M

+12.1%

Accounts Receivable

CA$4.06K

-35.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$53.40K

N/A

Short Term Debt

CA$3.16M

+10.3%

Return on Assets

-8.49%

N/A

Return on Invested Capital

24.36%

N/A

Free Cash Flow

-CA$102.70K

+35.4%

Operating Cash Flow

-CA$102.70K

+35.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VPT.VVentriPoint Diagnostics Ltd.

VPT.VVentriPoint Diagnostics Ltd.CA$0.09+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BACBank of America

BACBank of America$51.33-4.88%

CRWVCoreWeave

CRWVCoreWeave$65.84-15.38%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$111.32-12.74%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$42.24+12.87%

CIFRCipher Digital

CIFRCipher Digital$10.14-10.58%

NVDANvidia

NVDANvidia$220.84-3.36%

SOFISoFi Technologies

SOFISoFi Technologies$14.16-7.08%

Questions About IZOZF

What is the current price of Izotropic?

Izotropic is trading at $0.11 per share.

What is the 52-week range for Izotropic?

Over the past 52 weeks, Izotropic has traded between $0.10 and $0.37.

How much debt does Izotropic have?

As of the most recent reporting period, Izotropic reported total debt of CA$2.29M.

How much cash does Izotropic have on hand?

Izotropic reported CA$41.19K in cash and cash equivalents in its most recent financial results.

What is Izotropic’s dividend yield?

Izotropic does not currently have a dividend yield.

Izotropic(OTC) IZOZF

Izotropic Financials at a Glance

IZOZF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Izotropic

IZOZF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Izotropic Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IZOZF

What is the current price of Izotropic?

What is the 52-week range for Izotropic?

How much debt does Izotropic have?

How much cash does Izotropic have on hand?

What is Izotropic’s dividend yield?

Premium Investing Services